ResMed initiated with an Overweight at JPMorgan

JPMorgan initiated coverage of ResMed (RMD) with an Overweight rating and A$37.60 price target The firm says ResMed is the global leader in the obstructive sleep apnea market. While therapeutics, including GLP-1s, have demonstrated meaningful clinical benefit for sleep apnea patients, they do not prohibit a positive view on continuous positive airway pressure, the analyst tells investors in a research note.